Ganciclovir-Resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 128-135

  Minces, Lucio R ^a   Nguyen, M Hong ^a   Mitsani, Dimitra ^a   Shields, Ryan K ^a   Kwak, Eun J ^a   Silveira, Fernanda P ^a   Abdel Massih, Rima ^a   Pilewski, Joseph M ^b   Crespo, Maria M ^b   Bermudez, Christian ^c   Bhama, Jay K ^c   Toyoda, Yoshiya ^c   Clancy, Cornelius J ^a,d  

^a Divisions of Infectious Diseases   (United States)

^b Pulmonary Medicine   (United States)

^c Department of Cardiothoracic Surgery ^*  (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CIDOFOVIR; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; MYCOPHENOLIC ACID; TACROLIMUS; VALGANCICLOVIR; VIRUS DNA;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BIOPSY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DRUG EFFECT; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY INJURY; LUNG TRANSPLANT RECIPIENT; MALE; MORBIDITY; MORTALITY; NEUTROPENIA; PATIENT HISTORY OF LUNG TRANSPLANTATION; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; RETRANSPLANTATION; RETROSPECTIVE STUDY; RISK FACTOR; TIME TO TREATMENT; TOXICITY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; VIREMIA;

ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; FEMALE; FOSCARNET; GANCICLOVIR; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VIREMIA; YOUNG ADULT;

EID: 84891538529     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00561-13     Document Type: Article

References (44)

1. Ettinger NA, Bailey TC, Trulock EP, Storch GA, Anderson D, Raab S, Spitznagel EL, Dresler C, Cooper JD. 1993. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group. Am. Rev. Respir. Dis. 147:1017-1023.
2. Patel N, Snyder LD, Finlen-Copeland A, Palmer SM. 2012. Is prevention the best treatment? CMV after lung transplantation. Am. J. Transplant. 12:539-544. http://dx.doi.org/10.1111/j.1600-6143.2011.03837.x.
3. Duncan SR, Grgurich WF, Iacono AT, Burckart GJ, Yousem SA, Paradis IL, Williams PA, Johnson BA, Griffith BP. 1994. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation.Am. J. Respir. Crit. Care Med. 150:146-152. http://dx.doi.org/10.1164/ajrccm.150.1.8025741.
4. Gerbase MW, Dubois D, Rothmeier C, Spiliopoulos A, Wunderli W, Nicod LP. 1999. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation. Chest 116:1265-1272. http://dx.doi.org/10.1378/chest.116.5.1265.
5. Gutierrez J, Piedrola G, Maroto MC. 1998. Value of cytomegalovirus (CMV) IgG avidity index for the diagnosis of primary CMV infection. J. Infect. Dis. 178:599-600. http://dx.doi.org/10.1086/517464.
6. Speich R, Thurnheer R, Gaspert A, Weder W, Boehler A. 1999. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirusdisease after lung transplantation. Transplantation 67:315-320. http://dx.doi.org/10.1097/00007890-199901270-00023.
7. Weill D, Lock BJ, Wewers DL, Young KR, Zorn GL, Early L, Kirklin JK, McGiffin DC. 2003. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction. Am. J. Transplant. 3:492-496. http://dx.doi.org/10.1034/j.1600-6143.2003.00074.x.
8. Zamora MR, Nicolls MR, Hodges TN, Marquesen J, Astor T, Grazia T, Weill D. 2004. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am. J. Transplant. 4:1635-1642. http://dx.doi.org/10.1111/j.1600-6143.2004.00571.x.
9. Wreghitt TG, Abel SJ, McNeil K, Parameshwar J, Stewart S, Cary N, Sharples L, Large S, Wallwork J. 1999. Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients. Transpl. Int. 12:254-260. http://dx.doi.org/10.1111/j.1432-2277.1999.tb01210.x.
10. Valentine VG, Weill D, Gupta MR, Raper B, Laplace SG, Lombard GA, Bonvillain RW, Taylor DE, Dhillon GS. 2008. Ganciclovir for cytomegalovirus: A call for indefinite prophylaxis in lung transplantation. J. Heart Lung Transplant. 27:875-881. http://dx.doi.org/10.1016/j.healun.2008.05.009.
11. Hodson EM, Barclay PG, Craig JC, Jones C, Kable K, Strippoli GF, Vimalachandra D, Webster AC. 2005. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst. Rev. 2:CD003774. http://dx.doi.org/10.1002/14651858.CD003774.pub3.
12. Couchoud C. 2000. Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation. Cochrane Database Syst. Rev. 2:CD001320. http://dx.doi.org/10.1002/14651858.CD001320.pub2.
13. Humar A, Kumar D, Preiksaitis J, Boivin G, Siegal D, Fenton J, Jackson K, Nia S, Lien D. 2005. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am. J. Transplant. 5:1462-1468. http://dx.doi.org/10.1111/j.1600-6143.2005.00866.x.
14. Jaksch P, Zweytick B, Kerschner H, Hoda AM, Keplinger M, Lang G, Aigner C, Klepetko W. 2009. Cytomegalovirus prevention in high-risk lung transplant recipients: Comparison of 3- vs 12-month valganciclovir therapy. J. Heart Lung Transplant. 8:670-675. http://dx.doi.org/10.1016/j.healun.2009.03.012.
15. Monforte V, Lopez C, Santos F, Zurbano F, de la Torre M, Sole A, Gavalda J, Ussetti P, Lama R, Cifrian J, Borro JM, Pastor A, Len O, Bravo C, Roman A. 2009. A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients. Am. J. Transplant. 9:1134-1141. http://dx.doi.org/10.1111/j.1600-6143.2009.02574.x.
16. Chmiel C, Speich R, Hofer M, Michel D, Mertens T, Weder W, Boehler A. 2008. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus- related events and bronchiolitis obliterans syndrome after lung transplantation. Clin. Infect. Dis. 46:831-839. http://dx.doi.org/10.1086/528689.
17. Palmer SM, Limaye AP, Banks M, Gallup D, Chapman J, Lawrence EC, Dunitz J, Milstone A, Reynolds J, Yung GL, Chan KM, Aris R, Garrity E, Valentine V, McCall J, Chow SC, Davis RD, Avery R. 2010. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: A randomized, controlled trial. Ann. Intern. Med. 152:761- 769. http://dx.doi.org/10.7326/0003-4819-152- 12-201006150-00003.
18. Finlen Copeland CA, Davis WA, Snyder LD, Banks M, Avery R, Davis RD, Palmer SM. 2011. Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: A single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial. J. Heart Lung Transplant. 30:990-996. http://dx.doi.org/10. 1016/j.healun.2011.02.017.
19. Mitsani D, Nguyen MH, Kwak EJ, Silveira FP, Vadnerkar A, Pilewski J, Crespo M, Toyoda Y, Bermudez C, Clancy CJ. 2010. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis. J. Heart Lung Transplant. 29:1014-1020. http://dx.doi.org/10.1016/j.healun.2010.04.022.
20. Limaye AP. 2002. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin. Infect. Dis. 35:866-872. http://dx.doi.org/10.1086/ 342385.
21. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. 2002. High incidence of ganciclovir-resistant cytomegalovirus infectionamong lung transplant recipients receiving preemptive therapy. J. Infect.Dis. 185:20-27. http://dx.doi.org/10.1086/338143.
22. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. 2000. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid- organ transplants. Lancet 356:645-649. http://dx.doi.org/10.1016/S0140-6736(00)02607- 6.
23. Kruger RM, Shannon WD, Arens MQ, Lynch JP, Storch GA, Trulock EP. 1999. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation 68:1272-1279. http://dx.doi.org/10.1097/ 00007890-199911150-00010.
24. Isada CM, Yen-Lieberman B, Lurain NS, Schilz R, Kohn D, Longworth DL, Taege AJ, Mossad SB, Maurer J, Flechner SM, Mawhorter SD, Braun W, Gordon SM, Schmitt SK, Goldman M, Long J, Haug M, Avery RK. 2002. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection. Transplant Infect. Dis. 4:189-194. http://dx.doi.org/10.1034/j.1399-3062.2002.t01-1-02008.x.
25. Lurain NS, Chou S. 2010. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 23:689-712. http://dx.doi.org/10.1128/ CMR.00009-10.
26. Biron KK. 2006. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 71:154-163. http://dx.doi.org/10.1016/j.antiviral.2006.05.002.
27. Myhre HA, Haug Dorenberg D, Kristiansen KI, Rollag H, Leivestad T, Asberg A, Hartmann A. 2011. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation 92:217- 223. http://dx.doi.org/10.1097/TP.0b013e31821fad25.
28. Reddy AJ, Zaas AK, Hanson KE, Palmer SM. 2007. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: Treatment and outcome. J. Heart Lung Transplant. 26:1286- 1292. http://dx.doi.org/10.1016/j.healun.2007.09.012.
29. Bhorade SM, Lurain NS, Jordan A, Leischner J, Villanueva J, Durazo R, Creech S, Vigneswaran WT, Garrity ER. 2002. Emergence of ganciclovirresistant cytomegalovirus in lung transplant recipients. J. Heart Lung Transplant. 21:1274-1282. http://dx.doi.org/10.1016/S1053-2498(02)00463-1.
30. Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. 2008. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: Therapeutic implications and outcomes. Clin. Transplant. 22: 162-170. http://dx.doi.org/10.1111/j.1399-0012.2007.00761.x.
31. Li F, Kenyon KW, Kirby KA, Fishbein DP, Boeckh M, Limaye AP. 2007. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin. Infect. Dis. 45:439-447. http://dx.doi.org/10.1086/519941.
32. Sanghavi SK, Abu-Elmagd K, Keightley MC, St George K, Lewandowski K, Boes SS, Bullotta A, Dare R, Lassak M, Husain S, Kwak EJ, Paterson DL, Rinaldo CR. 2008. Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients. J. Clin.Virol. 42:335-342. http://dx.doi.org/10.1016/j.jcv.2008.03.031.
33. Husain S, Raza K, Pilewski JM, Zaldonis D, Crespo M, Toyoda Y, Shutt K, Spichty K, Bentlejewski C, Pakstis DL, Carey ME, McCurry KR, Zeevi A. 2009. Experience with immune monitoring in lung transplant recipients: Correlation of low immune function with infection. Transplantation 87:1852-1857. http://dx.doi.org/10.1097/TP.0b013e3181a75ad2.
34. Humar A, Kumar D, Boivin G, Caliendo AM. 2002. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J. Infect. Dis. 186:829-833. http://dx.doi.org/10. 1086/342601.
35. Acosta B, Ferrer D, Jordan M, Gonzalez D, Gobernado M. 1991. [Detection of cytomegalovirus in urine by the shell-vial technique: usefulness of diluting the sample]. Enferm. Infecc. Microbiol. Clin. 9:561-563. (In Spanish.)
36. Lurain NS, Fox AM, Lichy HM, Bhorade SM, Ware CF, Huang DD, Kwan SP, Garrity ER, Chou S. 2006. Analysis of the human cytomegalovirus genomic region from UL146 through UL147A reveals sequence hypervariability, genotypic stability, and overlapping transcripts. Virol. J. 3:4. http://dx.doi.org/10. 1186/1743-422X-3-4.
37. Snydman DR, Limaye AP, Potena L, Zamora MR. 2011. Update and review: State-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant. Proc. 43:S1- S17. http://dx.doi.org/10.1016/j.transproceed.2011.02.069.
38. Sharland M, Luck S, Griffiths P, Cotton M. 2011. Antiviral therapy of CMVdisease in children. Adv. Exp. Med. Biol. 697:243-260. http://dx.doi.org/10. 1007/978-1-4419-7185-2-17.
39. Chou S, Waldemer RH, Senters AE, Michels KS, Kemble GW, Miner RC, Drew WL. 2002. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J. Infect. Dis. 185:162-169. http://dx.doi.org/ 10.1086/338362.
40. Hakki M, Chou S. 2011. The biology of cytomegalovirus drug resistance. Curr. Opin. Infect. Dis. 24:605-611. http://dx.doi.org/10.1097/QCO. 0b013e32834cfb58.
41. Schreiber A, Harter G, Schubert A, Bunjes D, Mertens T, Michel D. 2009. Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin. Pharmacother. 10:191-209. http://dx.doi.org/10.1517/14656560802678138.
42. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P, Chakraverty R, Marshall T, Osman H, Mahendra P, Craddock C, Waldmann H, Hale G, Fegan CD, Yong K, Goldstone AH, Linch DC, Milligan DW. 2002. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of Campath-1H in delaying immune reconstitution. Blood 99:4357-4363. http://dx.doi.org/10.1182/blood.V99.12.4357.
43. Martin M, Goyette N, Ives J, Boivin G. 2010. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. J. Clin. Virol. 47:321-324. http://dx.doi.org/10.1016/j.jcv.2010.01.009.
44. Boivin G, Goyette N, Gilbert C, Covington E. 2005. Analysis of cytomegalovirusDNApolymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or ganciclovir prophylaxis. J. Med. Virol. 77:425-429. http://dx.doi.org/10.1002/jmv.20471.